Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: A framework for evaluating stratification using routine clinical and individual trial data

Diabetes Care

Volumn 41, Issue 9, 2018, Pages 1844-1853

  Dennis, John M ^a   Henley, William E ^a   Weedon, Michael N ^a   Lonergan, Mike ^b   Rodgers, Lauren R ^a   Jones, Angus G ^a,c   Hamilton, William T ^a   Sattar, Naveed ^d   Janmohamed, Salim ^e   Holman, Rury R ^f,g   Pearson, Ewan R ^b   Shields, Beverley M ^a   Hattersley, Andrew T ^a,c  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; METFORMIN; SULFONYLUREA DERIVATIVE;

BODY MASS; BODY WEIGHT GAIN; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG SAFETY; EDEMA; FEMALE; FRACTURE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; ADULT; AGED; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; GLUCOSE BLOOD LEVEL; INFORMATION PROCESSING; META ANALYSIS; METABOLISM; MIDDLE AGED; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX FACTOR; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; COST-BENEFIT ANALYSIS; DATASETS AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEX FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; UNITED KINGDOM;

EID: 85054644140     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-0344     Document Type: Conference Paper

References (44)

1. Qaseem A, Barry MJ, Humphrey LL, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017; 166: 279-290
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
3. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline (NG28). London, National Institute for Health and Care Excellence, 2015
4. Hingorani AD, Windt DA, Riley RD, et al.; PROGRESS Group. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013; 346:e5793
5. Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usagein the U.S.: real-world evidencein patients newly diagnosed with type 2 diabetes. Diabetes Care 2018; 41:69-78
6. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care 2017; 40:468-475
7. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443
8. Kahn SE, Zinman B, Lachin JM, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31:845-851
9. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48:1726-1735
10. Jones NP, Curtis PS, Home PD. Cancer and bone fractures in observational follow-up of the RECORD study. Acta Diabetol 2015; 52:539-546
11. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive Investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32:187-202
12. Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI, Hennessy S. Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin. J Comp Eff Res 2014; 3:29-39
13. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med 2006; 23:128-133
14. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125-2135
15. ClinicalStudyDataRequest.com [Internet]. Available from https://clinicalstudydatarequest.com/. Accessed 14 July 2017
16. Strom BL, Buyse ME, Hughes J, Knoppers BM. Data sharing - is the juice worth the squeeze? N Engl J Med 2016; 375:1608-1609
17. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25:1737-1743
18. Viberti G, Lachin J, Holman R, et al.; ADOPT Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med 2006; 23:1289-1294
19. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3:89-99
20. Rodgers LR, Weedon MN, Henley WE, Hattersley AT, Shields BM. Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open 2017; 7: e017989
21. Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care 2016; 39:258-263
22. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412
23. Jones AG, Lonergan M, Henley WE, Pearson ER, Hattersley AT, Shields BM. Should studies of diabetes treatment stratification correct for baseline HbA1c? PLoS One 2016; 11:e0152428
24. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia 2017; 60:769-777
25. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6:361-369
26. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467-477
27. McDermott U. Next-generation sequencing and empowering personalised cancer medicine. Drug Discov Today 2015; 20:1470-1475
28. Zhou K, Donnelly L, Burch L, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2010; 87:52-56
29. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56:2178-2182
30. Dawed AY, Donnelly L, Tavendale R, et al. CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes. Diabetes Care 2016; 39:1902-1908
31. Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC Investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43:117-120
32. Buzzetti R, Prudente S, Copetti M, et al. Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: a position statement of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis 2017; 27:99-114
33. Dennis JM, Shields BM, Hill AV, et al.; MASTERMIND Consortium. Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care 2018; 41: 705-712
34. Jones AG, McDonald TJ, Shields BM, et al.; PRIBA Study Group. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 2016; 39:250-257
35. Cantrell RA, Alatorre CI, Davis EJ, et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 2010; 12:845-857
36. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010; 95:1566-1574
37. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014; 68:115-123
38. Cohen D. Rosiglitazone: what went wrong? BMJ 2010; 341:c4848
39. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11:115-128
40. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies [published correction appears in Lancet 2004; 363:902]. Lancet 2004; 363:157-163
41. Zinman B, Wanner C, Lachin JM, et al.; EMPA-OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-2128
42. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311-322
43. Nathan DM, Buse JB, Kahn SE, et al.; GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013; 36:2254-2261
44. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115(Suppl. 8A):42S-48S